Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Obinutuzumab in Large B-cell lymphoma: NCT06567366 Clinical Landscape Report 2026
15 October 2026
NCT06567366 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[68Ga]Ga-NNS309 in Locally Advanced Unresectable Breast Carcinoma: NCT06562192 Clinical Landscape Report 2026](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_12_7f0c44f64f.jpg)
9 min read
[68Ga]Ga-NNS309 in Locally Advanced Unresectable Breast Carcinoma: NCT06562192 Clinical Landscape Report 2026
15 October 2026
NCT06562192 clinical landscape for Locally Advanced Unresectable Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developm…
9 min read
JWCAR201 in Large B-cell lymphoma: NCT06567080 Clinical Landscape Report 2026
15 October 2026
NCT06567080 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MK-1708 in Alzheimer Disease: NCT06566963 Clinical Landscape Report 2026
15 October 2026
NCT06566963 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TQB3702 in B-Cell Lymphoma: NCT06566586 Clinical Landscape Report 2026
15 October 2026
NCT06566586 clinical landscape for B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eniluracil in Triple Negative Breast Cancer: NCT06568692 Clinical Landscape Report 2026
15 October 2026
NCT06568692 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Chidamide in Diffuse large B-cell lymphoma refractory: NCT06570447 Clinical Landscape Report 2026
15 October 2026
NCT06570447 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Rituximab in Diffuse Large B-Cell Lymphoma: NCT06573645 Clinical Landscape Report 2026
15 October 2026
NCT06573645 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trilaciclib Dihydrochloride in Diffuse Large B-Cell Lymphoma: NCT06569485 Clinical Landscape Report 2026
15 October 2026
NCT06569485 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cadonilimab in Renal Cell Carcinoma: NCT06574412 Clinical Landscape Report 2026
15 October 2026
NCT06574412 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CID-078 in Recurrent Lung Small Cell Carcinoma: NCT06577987 Clinical Landscape Report 2026
15 October 2026
NCT06577987 clinical landscape for Recurrent Lung Small Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Vorolanib in Renal Cell Carcinoma: NCT06577961 Clinical Landscape Report 2026
15 October 2026
NCT06577961 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.